Risedronate: A Review of its Pharmacological Properties and Clinical Use in Resorptive Bone Disease

Dunn, C.J.; Goa, K.L.
March 2001
Drugs;Mar2001, Vol. 61 Issue 5, p685
Academic Journal
Risedronate is a novel orally administered pyridinyl bisphosphonate indicated for the prevention or treatment of postmenopausal and glucocorticoid-induced osteoporosis and Paget's disease. The drug reduces bone turnover and decreases resorption chiefly through osteoclastic effects, with no undesirable effects on cortical porosity or thickness or on cancellous bone volume. Four randomised, double-blind trials have been carried out in 4873 patients with postmenopausal osteoporosis. In 2 of these studies, the primary end-point of vertebral fracture incidence was reduced by risedronate 5mg once daily by up to 65 and 49% relative to placebo after 1 and 3 years, respectively. Across all 4 trials, risedronate improved lumbar spine, femoral neck and femoral trochanter bone mineral density (BMD) statistically significantly relative to placebo. The drug also prevented bone loss in a study in 383 women with recent menopause, and reduced the risk of hip fracture in elderly women with confirmed osteoporosis in a trial involving a total of 9331 patients. Risedronate 5 mg/day plus estrogen has been shown to be superior to estrogen alone in a 12-month double-blind study in 524 women with at least 1-year's history of menopause. Two randomised, double-blind and placebo-controlled 12-month studies in a total of 518 patients have shown risedronate 5 mg/day to prevent or reverse bone loss in patients receiving glucocorticoid therapy. Risedronate 30 mg/day was associated with statistically significant reductions in mean serum levels of alkaline phosphatase (ALP) in noncomparative studies in patients with Paget's disease. ALP normalisation rates ranged from 53.8 to 65% across two 84-day treatment cycles in 2 of these trials in 180 patients. In a randomised, double-blind study in 123 patients, risedronate 30 mg/day for 2 months evoked significantly greater serum ALP responses than etidronate 400 mg/day for 6 months. The overall tolerability profile of risedronate was similar to that of placebo in clinical studies, with no evidence of acute-phase reactions or mineralisation defects, or excess incidence of upper GI lesions, in patients receiving the drug. Conclusions: Risedronate is an effective and well tolerated novel bisphosphonate that is suitable for first-line therapy in Paget's disease. The rapid and sustained reductions in vertebral fracture incidence and BMD changes seen in patients with postmenopausal and glucocorticoid-induced osteoporosis indicate the drug to be a valuable treatment option with first-line potential, particularly in patients for whom hormonal therapy is inappropriate. The effects of the drug on hip fracture incidence in elderly women with confirmed osteoporosis point to a particular role in older patients, or those with more advanced disease.


Related Articles

  • Protecting Bone During Glucocorticoid Treatment. Kuritz, Louis // Internal Medicine Alert;1/29/2008, Vol. 30 Issue 2, p8 

    The article offers guidelines on how patients receiving long term Glucocorticoid treatment can prevent bone loss and reduce the risk of fractures.

  • New indication.  // Geriatrics;Aug99, Vol. 54 Issue 8, p12 

    Reports on the approved additional indication of alendronate sodium or Fosamax, the treatment of glucocorticoid-induced osteoporosis in men and women. Findings of a study conducted on the treatment; Dosage recommendations for the treatment of low bone mass in men and women receiving...

  • Genetics of Glucocorticoids in Asthma.  // New England Journal of Medicine;12/22/2011, Vol. 365 Issue 25, p2434 

    A letter to the editor is presented in response to an article about the significant association between the GLCCI1 variant rs37972 and the response to glucocorticoid therapy in asthma patients by K. G. Tantisira in the September 29, 2011 issue.

  • Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Saag, Kenneth G.; Emkey, Ronald; Schnitzer, Thomas J.; Brown, Jacques P.; Hawkins, Federico; Goemaere, Stefan; Thamsborg, Gorm; Liberman, Uri A.; Delmas, Pierre D.; Malice, Marie-Pierre; Czachur, Michelle; Daifotis, Anastasia G.; Lane, Nancy; Correa-Rotter, Ricardo; Yanover, Melissa; Westhovens, Rene; Epstein, Sol; Adachi, Jonathan D.; Poubelle, Patrice; Melo-Gomes, Jose // New England Journal of Medicine;07/30/98, Vol. 339 Issue 5, p292 

    Background: Osteoporosis is a common complication of long-term glucocorticoid therapy for which there is no well-proved preventive or restorative treatment. Methods: We carried out two 48-week, randomized, placebo-controlled studies of two doses of alendronate in 477 men and women, 17 to 83...

  • Comparison of the Systemic Availability of Fluticasone Propionate in Healthy Volunteers and Patients with Asthma. Daley-Yates, P.T.; Tournant, J.; Kunka, R.L. // Clinical Pharmacokinetics;2000 Supplement, Vol. 39 Issue 6, p39 

    Objectives: The aim of this analysis was to compare the systemic exposure to inhaled fluticasone propionate (FP) after administration of either single or repeated dose regimens via dry powder and metered-dose inhalers in patients with asthma and healthy volunteers. Background: The...

  • From the editors.  // Nature Reviews Neuroscience;Oct2010, Vol. 11 Issue 10, p661 

    An introduction to the journal is presented in which the editors discuss an article concerning the formulation of SNARE hypothesis of intracellular membrane fusion, the therapeutic use of glucocorticoid stress hormones by Lightman and Conway-Campbell, and the role of glucocorticoids in promoting...

  • Treatment and Outcome of Congenital Adrenal Hyperplasia: 21-Hydroxylase Deficiency. Lee, Peter A.; Fuqua, John S.; Nebesio, Todd D. // International Journal of Pediatric Endocrinology;2010, p1 

    An introduction is presented in which the editor discusses various reports within the issue on topics including the diagnosis and treatment of congenital adrenal hyperplasia (CAH), psychological management of CAH, and the use of glucocorticoids as a CAH treatment.

  • Lemmel's syndrome with cholangitis induced by glucocorticoid treatment. Fujita, T.; Satomura, A.; Matsumoto, K. // Clinical Nephrology;2006, Vol. 66 Issue 1, p74 

    A letter to the editor is presented in response to the article regarding Lemmel's syndrome with cholangitis induced by glucocorticoid treatment.

  • Corticosteroids/methylprednisolone.  // Reactions Weekly;6/18/2011, Issue 1356, p13 

    The article describes the case of a 13-year-old girl with dermatomyositis who developed multifocal osteonecrosis while undergoing oral glucocorticoid therapy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics